The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane

Williams, John D.; Topley, Nicholas; Craig, Kathrine J.; Mackenzie, Ruth K.; Pischetsrieder, Monika; Lage, Cristina; Passlick-Deetjen, Jutta
July 2004
Kidney International;Jul2004, Vol. 66 Issue 1, p408
Academic Journal
The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Background. Although peritoneal dialysis (PD) is a widely accepted form of renal replacement therapy (RRT), concerns remain regarding the bioincompatible nature of standard PD fluid. In order to evaluate whether a newly formulated fluid of neutral pH, and containing low levels of glucose degradation products (GDP), resulted in improved in vivo biocompatibility, it was compared in a clinical study to a standard PD fluid. Methods. In a multicenter, open, randomized, prospective study with a crossover design and parallel arms, a conventional, acidic, lactate-buffered fluid (SPDF) was compared with a pH neutral, lactate-buffered, low GDP fluid (balance). Overnight effluent was collected and assayed for cancer antigen 125 (CA125), hyaluronic acid (HA), procollagen peptide (PICP), vascular endothelial growth factor (VEGF), and tumor necrosis factor alpha (TNFα). Serum samples were assayed for circulating advanced glycosylation end products (AGE), Nε-(carboxymethyl)lysine (CML), and imidazolone. Clinical end points were residual renal function (RRF), adequacy of dialysis, ultrafiltration, and peritoneal membrane function. Eighty-six patients were randomized to either group I starting with SPDF for 12 weeks (Phase I), then switching to “balance” for 12 weeks (Phase II), or group II, which was treated vice versa. Seventy-one patients completed the study with data suitable for entry into the per protocol analysis. Effluent and serum samples, together with peritoneal function tests and adequacy measurements, were undertaken at study centers on three occasions during the study: after the four-week run-in period, after Phase I, and again after Phase II. Results. In patients treated with balance there were significantly higher effluent levels of CA125 and PICP in both arms of the study. Conversely, levels of HA were lower in patients exposed to balance, while there was no change in the levels of either VEGF or TNFα. Serum CML and imidazolone levels fell significantly in balance-treated patients. Renal urea and creatinine clearances were higher in both treatment arms after patients were exposed to balance. Urine volume was higher in patients exposed to balance. In contrast, peritoneal ultrafiltration was higher in patients on SPDF. When anuric patients were analyzed as a subgroup, there was no significant difference in peritoneal transport characteristics or in ultrafiltration on either fluid. There were no changes in peritonitis incidence on either solution. Conclusion. This study indicates that the use of balance, a neutral pH, low GDP fluid, is accompanied by a significant improvement in effluent markers of peritoneal membrane integrity and significantly decreased circulating AGE levels. Clinical parameters suggest an improvement in residual renal function on balance, with an accompanying decrease in peritoneal ultrafiltration. It would appear that balance solution results in an improvement in local peritoneal homeostasis, as well as having a positive impact on systemic parameters, including circulating AGE and residual renal function.


Related Articles

  • Rationale and design of the balANZ trial: A randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function. Johnson, David W.; Clarke, Margaret; Wilson, Vanessa; Woods, Feidhlim; Brown, Fiona G. // BMC Nephrology;2010, Vol. 11, p25 

    Background: The main hypothesis of this study is that neutral pH, low glucose degradation product (GDP) peritoneal dialysis (PD) fluid better preserves residual renal function in PD patients over time compared with conventional dialysate. Methods/Design: Inclusion criteria are adult PD patients...

  • Peritoneal equilibration test with conventional ‘low pH/high glucose degradation product’ or with biocompatible ‘normal pH/low glucose degradation product’ dialysates: does it matter? Van Overmeire, Lionel; Goffin, Eric; Krzesinski, Jean-Marie; Saint-Remy, Annie; Bovy, Philippe; Cornet, Georges; Bovy, Christophe // Nephrology Dialysis Transplantation;Jul2013, Vol. 28 Issue 7, p1946 

    Background The evaluation of the peritoneal transport characteristics is mandatory in peritoneal dialysis (PD) patients. This is usually performed in routine clinical practice with a peritoneal equilibration test (PET) using conventional dialysates, with low pH and high glucose degradation...

  • Buffer transport in peritoneal dialysis. Heimburger, Olof; Mujais, Salim // Kidney International Supplement;Dec2003, Issue 88, pS37 

    Buffer transport in peritoneal dialysis. The success of peritoneal dialysis as a robust modality of renal replacement therapy has invited a quest for ameliorations in its underlying technology aimed at enhancing patient satisfaction and preserving the central instrument of the therapy, namely...

  • In vitro biocompatibility performance of Physioneal. Horr, Catherine M. // Kidney International Supplement;Dec2003, Issue 88, pS57 

    In vitro biocompatibility performance of Physioneal. Peritoneal dialysis (PD) has been a successful and effective form of chronic renal replacement therapy since its introduction over 20 years ago. Despite its overall success, there is a growing body of evidence that suggests shortcomings in...

  • Uremic toxins and peritoneal dialysis. Lameire, Norbert; Vanholder, Raymond; De Smet, Rita // Kidney International Supplement;Feb2001, Issue 78, pS-292 

    Analyzes the generation and removal of uremic toxins in peritoneal dialysis patients. Involvement of uremic toxins in the progression of renal failure; Characteristics of dialysis-related amyloidosis; Similarity of positive scans in peritoneal dialysis patients and hemodialysis patients.

  • Effect of continuous ambulatory peritoneal dialysis on a British renal unit. Morgan, A.G.; Burden, R.P. // British Medical Journal (Clinical Research Edition);10/11/1986, Vol. 293 Issue 6552, p935 

    Investigates the effects of continuous ambulatory peritoneal dialysis (CAPD) on a renal unit in Great Britain. Percentage of actuarial survival of patients transferring to hemodialysis; Suitability of hospital hemodialysis for patients; Importance in the selection of patients to reduce mortality.

  • Dialysis outcome depends on patient condition at initiation.  // Kidney;Sep/Oct2002, Vol. 11 Issue 5, p215 

    Presents a summary of the study 'Peritoneal and Hemodialysis: II. Mortality Risk Associated With Initial Patient Characteristics,' by J.L. Xue, S.E. Everson et al., from a 2002 of 'Kidney International.'

  • Survival differences between peritoneal dialysis and hemodialysis among “large” ESRD patients in the United States. Stack, Austin G.; Murthy, Bhamidipati V. R.; Molony, Donald A. // Kidney International;Jun2004, Vol. 65 Issue 6, p2398 

    Survival differences between peritoneal dialysis and hemodialysis among “large” ESRD patients in the United States. Background. It has been hypothesized that peritoneal dialysis compared to hemodialysis may be less effective in large patients with end-stage renal disease (ESRD)....

  • Study: Patient Survival Better with HHD than PD.  // Renal & Urology News;Jun2015, Vol. 14 Issue 5, p9 

    The article reports on the study which reveals the effectiveness of home hemodialysis (HHD) against peritoneal dialysis (PD) to have lesser mortality rate among kidney disease patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics